/
Oncotarget
Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma
- V. Arnhold
- K. Schmelz
- J. Proba
- A. Winkler
- J. Wünschel
- J. Toedling
- H.E. Deubzer
- A. Künkele
- A. Eggert
- J.H. Schulte
- P. Hundsdoerfer